Cytokines & Chemokines

CD244 (Cluster of Differentiation 244) is a human protein encoded by the CD244 gene. It is also known as Natural Killer Cell Receptor 2B4. This gene encodes a cell surface receptor expressed on natural killer cells (NK cells) (and some T cells) mediating non-major histocompatibility complex (MHC) restricted killing. The interaction between NK-cell and target cells via this receptor is thought to modulate NK-cell cytolytic activity. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. CD244 can also be expressed on non-lymphocytes such as eosinophils, mast cells and dendritic cells.

CD244 (Cluster of Differentiation 244) is a human protein encoded by the CD244 gene. It is also known as Natural Killer Cell Receptor 2B4. This gene encodes a cell surface receptor expressed on natural killer cells (NK cells) (and some T cells) mediating non-major histocompatibility complex (MHC) restricted killing. The interaction between NK-cell and target cells via this receptor is thought to modulate NK-cell cytolytic activity. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. CD244 can also be expressed on non-lymphocytes such as eosinophils, mast cells and dendritic cells.

GITR Ligand, also known as TNFSF18 and TL6, is an approximately 30 kDa type II transmembrane glycoprotein in the TNF superfamily (1). Human GITR Ligand consists of a 50 amino acid cytoplasmic domain, a 21 aa transsmembrane segment, and a 128 aa extracellular domain (ECD). Within the ECD, human GITR Ligand shares 56% and 60% aa sequence identity with mouse and rat GITR Ligand, respectively. TNFSF18 is expressed at high levels in the small intestine, ovary, testis, kidney and endothelial cells. GITRL/TNFSF18 is up-regulated after stimulation by bacterial lipopolysaccharides (LPS). TNFSF18 Can function as costimulator and lower the threshold for T-cell activation and T-cell proliferation. TNFSF18 / GITR Ligand is important for interactions between activated T-lymphocytes and endothelial cells.Recombinant Human GITR Ligand Fc Chimera produced in HEK293 cells is a polypeptide chain containing 359 amino acids with the C-termimal human IgG1 Fc fragment. A fully biologically active molecule, r

GITR Ligand, also known as TNFSF18 and TL6, is an approximately 30 kDa type II transmembrane glycoprotein in the TNF superfamily (1). Human GITR Ligand consists of a 50 amino acid cytoplasmic domain, a 21 aa transsmembrane segment, and a 128 aa extracellular domain (ECD). Within the ECD, human GITR Ligand shares 56% and 60% aa sequence identity with mouse and rat GITR Ligand, respectively. TNFSF18 is expressed at high levels in the small intestine, ovary, testis, kidney and endothelial cells. GITRL/TNFSF18 is up-regulated after stimulation by bacterial lipopolysaccharides (LPS). TNFSF18 Can function as costimulator and lower the threshold for T-cell activation and T-cell proliferation. TNFSF18 / GITR Ligand is important for interactions between activated T-lymphocytes and endothelial cells.Recombinant Human GITR Ligand Fc Chimera produced in HEK293 cells is a polypeptide chain containing 359 amino acids with the C-termimal human IgG1 Fc fragment. A fully biologically active molecule, r

CD160 is a glycosylphosphatidylinositol-anchored Ig domain protein that is expressed on almost all intestinal intraepithelial lymphocytes (IELs), γδ T (gamma delta T) cells, NK (natural killer) cells, and a minor subset of CD4+ and CD8+ T cells. In terms of function, work has centered on the role of CD160 in enhancing NK or CD8 T cell activation. Such effects have been attributed to the ability of CD160 to bind classical and nonclassical MHC class I molecules, although with apparent low affinity, requiring clustering of MHC class I molecules or overexpression of CD160 or MHC class I for detection of the interaction.

CD160 is a glycosylphosphatidylinositol-anchored Ig domain protein that is expressed on almost all intestinal intraepithelial lymphocytes (IELs), γδ T (gamma delta T) cells, NK (natural killer) cells, and a minor subset of CD4+ and CD8+ T cells. In terms of function, work has centered on the role of CD160 in enhancing NK or CD8 T cell activation. Such effects have been attributed to the ability of CD160 to bind classical and nonclassical MHC class I molecules, although with apparent low affinity, requiring clustering of MHC class I molecules or overexpression of CD160 or MHC class I for detection of the interaction.

CD160 is a glycosylphosphatidylinositol-anchored Ig domain protein that is expressed on almost all intestinal intraepithelial lymphocytes (IELs), γδ T (gamma delta T) cells, NK (natural killer) cells, and a minor subset of CD4+ and CD8+ T cells. In terms of function, work has centered on the role of CD160 in enhancing NK or CD8 T cell activation. Such effects have been attributed to the ability of CD160 to bind classical and nonclassical MHC class I molecules, although with apparent low affinity, requiring clustering of MHC class I molecules or overexpression of CD160 or MHC class I for detection of the interaction.

CD70 (Cluster of Differentiation 70) is a protein that in humans is encoded by CD70 gene. CD70 is a ligand for CD27. The CD70-CD27 pathway plays an important role in the generation and maintenance of T cell immunity, in particular during antiviral responses. Upon CD27 binding, induces the proliferation of costimulated T-cells and enhances the generation of cytolytic T-cells.The CD70 protein is expressed on highly activated lymphocytes (like in T- and B-cell lymphomas). It is therefore suggested that anti-CD70 antibodies might be a possible treatment for CD70 positive lymphomas as normal lymphocytes have low CD70 expression.

CD70 (Cluster of Differentiation 70) is a protein that in humans is encoded by CD70 gene. CD70 is a ligand for CD27. The CD70-CD27 pathway plays an important role in the generation and maintenance of T cell immunity, in particular during antiviral responses. Upon CD27 binding, induces the proliferation of costimulated T-cells and enhances the generation of cytolytic T-cells.The CD70 protein is expressed on highly activated lymphocytes (like in T- and B-cell lymphomas). It is therefore suggested that anti-CD70 antibodies might be a possible treatment for CD70 positive lymphomas as normal lymphocytes have low CD70 expression.